Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Investment analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Moderna in a note issued to investors on Monday, January 13th. Brookline Capital Management ...

RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) on January 13 and set a price target of $40.00. The ...

We recently published a list of 11 Stocks That Will Go to the Moon According to Reddit. In this article, we are going to take ...

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...

CytomX Therapeutics, a Bay Area biotech firm with lucrative and high-profile partnerships in the industry, is laying off 40% ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...